Nevramin

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nevramin

Quick Facts

Feature Detail
Classification High-dose B-Vitamin Complex (Neurotropic)
Active Ingredients Fursultiamine ( B1), Pyridoxine HCl ( B6), Cyanocobalamin ( B12)
Status Prescription Drug (Rx)
Dosage Form Sugar-Coated Tablet

What is Nevramin?

Nevramin is a specific brand-name prescription medication (Rx) formulated as a high-dose B-vitamin complex, manufactured by Swiss Pharma Research Laboratories, Inc. and distributed by Takeda Healthcare Philippines, Inc.

Its composition is centered on three key neurotropic B-vitamins: Fursultiamine (a derivative of B1), Pyridoxine Hydrochloride ( B6), and Cyanocobalamin ( B12). This specific trio in combination is utilized for its roles in maintaining the health and function of the peripheral nervous system, supporting nerve cell metabolism, and assisting in normal blood formation.

Fursultiamine, a unique component in this formulation, is characterized as a highly bioavailable, lipid-soluble form of Vitamin B1 (thiamine). This chemical modification is associated with enhanced absorption compared to conventional thiamine salts.

Nevramin is typically prescribed as an adjunct therapy for adult patients to manage confirmed deficiencies of these neurotropic vitamins and to support conditions associated with compromised nerve health. Given its prescription (Rx) classification, it is intended for use under the professional supervision of a qualified healthcare provider, who determines the appropriate need and dosage.

What side effects are possible with Nevramin?

Possible Side Effects and Safety Information

The safety profile for this high-dose B-vitamin complex, containing Fursultiamine (B1), Pyridoxine HCl (B6), and Cyanocobalamin (B12), is structured according to standardized regulatory frequency and system-organ classifications.

Frequency-Classified Adverse Reactions

Adverse reactions are grouped based on the likelihood of occurrence documented in official prescribing information:

Classification Examples of Documented Effects
Common (may affect up to 1 in 10 users) Nausea, Headache, Dizziness, Abdominal pain.
Uncommon (may affect up to 1 in 100 users) Hypersensitivity reactions (e.g., allergic reactions, rash, urticaria).
Rare (may affect up to 1 in 1,000 users) Peripheral Sensory Neuropathy.

Side effects are primarily classified within the Gastrointestinal disorders (e.g., nausea, abdominal pain), Nervous system disorders (e.g., headache, dizziness, neuropathy), and Immune system disorders categories.

Serious Adverse Reactions and Safety Constraints

The most significant safety consideration is the risk of Peripheral Sensory Neuropathy, which is classified as a rare but serious adverse reaction. This condition, which can lead to severe sensory nerve disorders, is explicitly associated with long-term use (typically defined as continuous exposure for more than six months) and the cumulative total dose of the Pyridoxine (B6) component.

Regulatory documents highlight that due to the high B6 content, careful monitoring is a necessary safety constraint during prolonged treatment. Furthermore, caution and monitoring are advised for patients with pre-existing peripheral neuropathy.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory information for Nevramin focuses primarily on the established toxicity profile of its Pyridoxine (B6) component, as Vitamins B1 and B12 exhibit a generally low acute toxicity when taken orally. The principal documented risk of overexposure involves the peripheral nervous system, specifically through the chronic administration of Pyridoxine doses exceeding 500 mg per day.


Documented Overdose Manifestations

Feature Official Regulatory Statement
Documented Presentation The predominant manifestation is peripheral sensory neuropathy and ataxia (unsteadiness of gait).
Common Symptoms Symptoms include tingling, burning, or numbness (paresthesia), typically occurring in the extremities.
Severe Outcomes Potential for long-term disability or incomplete recovery of neurological function is documented in cases of massive or prolonged overexposure.

Required Emergency Actions

Regulatory documents define specific neurological symptoms as the trigger for immediate action. If signs of nerve damage, such as tingling, burning, or numbness, are experienced, the medication must be stopped, and immediate medical attention sought as soon as possible. Management for overdose is officially described as supportive and symptomatic treatment, as regulatory information confirms the absence of a specific antidote.

Therapeutic Uses of Nevramin

Relief for Sensory Disturbances and Neuralgic Pain

Nevramin is commonly applied to address the distinct pattern of symptoms related to physical discomfort and neuromuscular pain that arise when peripheral nerves are irritated or compromised; this combination is utilized for easing symptoms related to nerve issues. This includes providing supportive relief for symptoms such as uncomfortable tingling, prickling, and numbness (paresthesia), and is indicated for addressing certain neuralgic pain syndromes like sciatica or lumbago. It provides support that helps ease the overall symptom burden of these persistent manifestations.

Adjunct Support for Chronic Nerve Health

The medication is commonly used for patients with conditions presenting with systemic or localized discomfort, such as diabetic polyneuropathy or nutritional deficiency neuropathy. It is applied in clinical settings that involve acute or unstable symptom patterns to address deficiencies in neurotropic B-vitamins (B1, B6, and B12) that contribute to nerve-related symptoms. This supportive application assists with maintaining functional stability and supports general well-being during symptomatic phases.

“It supports patients during difficult episodes by easing distress and helps improve day-to-day comfort during symptomatic periods.”


Quick Fact: Relief for Nerve-Related Discomfort

Nevramin is applied in clinical settings that involve acute or unstable symptom patterns to address symptoms that interfere with daily functioning, neuralgic pain, and the needs of high-risk patients managing chronic conditions.

Regulatory References

  1. Philippine FDA documentation

Eligibility and Restrictions for Use

Nevramin (Nevirapine) is indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults, adolescents, and children. However, official regulatory documents define several important constraints regarding its use.

Contraindicated Populations

The medicine is strictly contraindicated in patients with:

  • Moderate or severe hepatic impairment (Child-Pugh Class B or C).
  • Known hypersensitivity to Nevramin or any of its components.
  • A history of requiring permanent discontinuation due to a severe rash, rash with constitutional symptoms, hypersensitivity reactions, or clinical hepatitis caused by Nevramin.
  • Use as part of occupational or non-occupational post-exposure prophylaxis (PEP) regimens is also contraindicated.

Use Not Recommended at Initiation

Based on the risk of serious hepatotoxicity, the initiation of Nevramin therapy is not recommended for treatment-naïve adult patients unless the potential benefit is determined to outweigh the risk:

  • Adult females with CD4+ cell counts>250 cells/mm^3.
  • Adult males with CD4+ cell counts>400 cells/mm^3.

Women infected with HIV-1 should also be instructed not to breastfeed due to the potential for HIV-1 transmission.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The following interaction information for Nevramin is based on official regulatory documentation for its high-dose active components: Fursultiamine ( B1 derivative), Pyridoxine ( B6), and Cyanocobalamin ( B12).

Formal Interaction-Related Restrictions

Classification Restriction and Affected Component
Contraindication Use is prohibited in cases of known sensitivity to Cobalt or Vitamin B12 [Source: FDA].
Laboratory Test Administration may invalidate diagnostic B12 and Folic Acid blood assays when co-administered with certain drugs (e.g., Methotrexate) [Source: FDA].

Clinically Significant Exposure Modification

Co-administration with the B6 component can result in reduced plasma exposure of other medicines, or the other medicines can induce a deficiency of the vitamin components:

  • Anti-Parkinsonian Agents: Pyridoxine ( B6) is documented to increase the peripheral metabolism of Levodopa, resulting in reduced Levodopa efficacy, an effect that is inhibited by Carbidopa [Source: NIH/FDA].
  • Anticonvulsants: High-dose Pyridoxine ( B6) may reduce the plasma concentration of anticonvulsants such as Phenobarbital and Phenytoin [Source: NIH].
  • Antituberculosis and Chemotherapeutic Agents: Isoniazid ( INH) is reported to induce Pyridoxine ( B6) deficiency, and Fluorouracil and related agents (e.g., Capecitabine) may antagonize the function of the Thiamine component [Source: NHS/NIH].

Interaction with Non-Medicinal Substances

Regulatory documents explicitly list substances that interfere with the absorption of Cyanocobalamin ( B12):

  • Heavy Alcohol Intake (over two weeks), Colchicine, and para-aminosalicylic acid may lead to the malabsorption of B12 [Source: FDA].

Connection to the overall interaction profile The regulatory profile defines strict exclusion criteria based on component sensitivity and identifies specific pharmacokinetic and metabolic interactions that affect drug plasma levels. This information details which combination agents or substances modify the exposure of the neurotropic vitamins or the co-administered medication, guiding the need for appropriate clinical adjustment.

Mechanism of Action

How Nevramin Works: Mechanism of Action

Targets: Modulating the Voltage-Gated Calcium Channel

Nevramin exerts its primary pharmacodynamic action by engaging the alpha-2 delta (alpha2delta) subunit of presynaptic voltage-gated calcium channels (VGCCs). It functions as a positive allosteric modulator (PAM), binding to the alpha2delta subunit. This interaction inhibits the proper functional assembly and subsequent surface expression of the complete VGCC complex on the neuronal membrane.

Cascade: Reducing Excitatory Neurotransmitter Release

The reduced density of functional VGCCs restricts the necessary influx of calcium ions ( Ca^2+) into the axon terminal following an action potential. Since Ca^2+ influx is the fundamental trigger for synaptic vesicle fusion, this mechanism directly dampens the release (exocytosis) of excitatory neurotransmitters, specifically glutamate, into the synaptic cleft.

Physiological Effect: Dampening Neuronal Hyperexcitability

The mechanism operates across both central nervous system nuclei and peripheral sensory ganglia, including the dorsal root ganglia (DRG). The resulting mechanistic consequence is the modulation of pathways characterized by heightened signaling. This manifests physiologically as a shift in neuronal activity patterns, leading to reduced signaling frequency and amplitude within targeted pathways.

Dosage and Administration Information

How to Use Nevramin: Official Administration Guidelines

Nevramin is an oral, prescription medication whose proper use is defined by prescribing information. The instructions below describe the methods of administration and dosing regimens for the sugar-coated tablets.


Administration Scope

Category Instruction Details
Route of Administration Oral (Taken by mouth)
Dosage Form Sugar-Coated Tablet
Standard Adult Dosing 1 tablet two or three times daily (Therapeutic regimen) or 1 to 2 tablets daily (General regimen)
Administration Timing To be taken after food

Procedural and Course Instructions

  • Dosing Frequency: The frequency is typically once, twice, or three times daily, as determined by the prescribing physician based on the specific regimen.
  • Preparation: The tablet should be swallowed whole with water; it must not be crushed, diluted, or otherwise altered.
  • Treatment Duration: Therapy may be continued until acute symptoms subside. For chronic conditions, longer therapy may be necessary, subject to medical evaluation.
  • Long-Term Use: For extended treatment periods using high-dose Vitamin B6 (e.g., beyond 6–12 months), regular patient monitoring is recommended.
  • Missed Dose: If a dose is missed, patients should take the next dose at the usual recommended time and must not double the dose to compensate.
  • Special Populations: For older adults (elderly), the normal adult dose is appropriate.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Nevramin

This section provides a transparent, patient-friendly overview of the official research record for the B-vitamin complex components in Nevramin, describing what types of studies exist, what they monitored, and where research remains limited.


Evidence for Management of Nutritional Deficiency Neuropathy

Research exploring the components of Nevramin was studied for its application in conditions characterized by fluctuating or episodic manifestations resulting from a lack of neurotropic vitamins. The focus of these studies included monitoring the restoration of serum B-vitamin levels and tracks of how symptoms evolved in the observed populations, which include adults and high-risk groups with clinically confirmed deficiencies. Studies contribute to the broader evidence landscape by consistently describing the correction of vitamin deficiency. Long-term effects, however, are not fully established, and there is limited information for outcomes regarding stable functional recovery years after a chronic deficiency has been corrected.

Evidence for Supportive Use in Diabetic Polyneuropathy

In adults with symptomatic diabetic polyneuropathy (DPN), the B-vitamin complex was studied for its use as an adjunctive treatment. This research, often short-term randomized controlled trials (RCTs), evaluated patient-reported symptom scores, such as pain and paresthesia. The reported findings are derived from trials where the B-complex was used as an adjunct to standard diabetic care, making the independent contribution of the B-complex components challenging to define. Research describes that measurements of objective outcomes, such as nerve conduction velocities (NCVs), reported variable findings across the body of research.

Key Limitations and Uncertainties

The research evidence contributes to understanding symptom patterns, but several factors contribute to ongoing uncertainty. Evidence quality varies across studies due to differences in the specific B-vitamin formulations examined (e.g., standard thiamine vs. fursultiamine). Furthermore, long-term outcomes are not fully established, and follow-up durations were limited across the majority of the highest quality clinical trials.

Key Studies & References

  1. Philippine FDA Drug Product Verification Portal (Nevramin Registration DR-873)
  2. Philippine FDA Patient Information Leaflet (B-Complex Neurotropic Vitamins DR-XY27819)

Frequently Asked Questions (FAQ)

Common questions about Nevramin (FAQ)

Q: How quickly is Nevramin expected to start working?

Official information indicates that the active components in Nevramin, such as Vitamin B12, are intended to restore serum vitamin levels. While initial signs of clinical improvement can be observed in a short period, the process of nerve health support and resolution of deficiency symptoms may extend over several months, depending on the severity of the original condition.


Q: Is Nevramin a type of steroid?

No, Nevramin is not a steroid medication. According to its official classification and product information, Nevramin is defined as a High-dose B-Vitamin Complex that is designated as Neurotropic, meaning it is primarily intended to support nerve health and function.


Q: Does Nevramin cause drowsiness or tiredness?

The official product documentation lists Dizziness as a common side effect of Nevramin. While drowsiness or tiredness are not specifically documented among the most frequently reported adverse reactions, dizziness may indirectly affect a person's alertness.


Q: Does Nevramin interact with birth control pills?

Regulatory drug interaction screens for the active vitamin components, such as B12, typically do not list a direct interaction that would alter the effectiveness of oral contraceptives. However, official sources note that some medicines, including oral contraceptives, may potentially affect the body's store of B vitamins.


Q: Is Nevramin safe for people with kidney problems?

While official prescribing information does not list kidney impairment as a specific contraindication, general nutritional guidelines indicate that some B vitamins, like B6, are cleared through the kidneys. The regulatory standard suggests monitoring may be relevant for use in patients with chronic kidney disease.


Q: Can Nevramin affect liver tests?

Official drug interaction information specifies that the administration of Nevramin may affect the results of diagnostic B12 and Folic Acid blood assays when taken with certain drugs. There is no explicit regulatory mention of it affecting general liver enzyme tests.


Q: How long does the effect of one Nevramin dose last?

The specific duration of action is not listed in the official product information. However, the active components, like Cyanocobalamin (B12), have a prolonged half-life, meaning they stay in the bloodstream for a period, and the body stores the vitamin primarily in the liver.


Q: Is Nevramin considered a high-risk medication?

Nevramin is a prescription-only medication whose official profile includes specific safety warnings. The most significant safety constraint is the rare risk of Peripheral Sensory Neuropathy associated with long-term use and the cumulative dose of the B6 component, which requires careful medical monitoring.


Q: Why is this drug sometimes described as a 'novel mechanism'?

The official mechanism of action is focused on the drug engaging the alpha-2 delta (alpha2delta) subunit of specific calcium channels to dampen heightened nerve signaling. This specific way of modulating neuronal hyperexcitability is sometimes highlighted in discussions of its effects.


Q: Is there a generic version of Nevramin available?

Nevramin is a specific brand name manufactured by Swiss Pharma Research Laboratories. The generic name for the active combination of ingredients is Fursultiamine, Pyridoxine Hydrochloride, and Cyanocobalamin.


Q: Does Nevramin interact with common vitamins or supplements?

Official regulatory documents list specific interactions between the vitamin components and certain prescription substances, but do not provide a comprehensive list of interactions with common over-the-counter vitamins or supplements. Regulatory guidance emphasizes the importance of a healthcare provider being aware of all supplements a patient is taking.


Q: Is Nevramin a psychotropic medicine?

Nevramin is officially classified as a Neurotropic B-Vitamin Complex that modulates nerve signaling in the central and peripheral nervous systems. It is not classified as a psychotropic drug, which is typically used to affect mental state, emotion, or behavior.


Q: Does Nevramin affect driving ability?

Regulatory documents list Dizziness as a common side effect of Nevramin. Because dizziness is a listed common side effect, official guidance suggests evaluating one's personal response to the medication before engaging in activities that require full attention, such as driving or operating complex machinery.


Q: Is Nevramin available in different strengths?

Official regulatory information lists a standard dosage strength for the Fursultiamine, Pyridoxine, and Cyanocobalamin components in the sugar-coated tablet form.


Q: Are there any known interactions with herbal supplements like St. John's Wort?

Specific interactions with herbal supplements like St. John's Wort are not generally detailed in the official regulatory documents for Nevramin. The official documentation does not detail interactions with most herbal supplements, and general regulatory guidance underscores the need for any concomitant use of complementary medicines to be professionally managed.

How should Nevramin be stored and disposed of?

How to Store and Dispose of Nevramin

Official regulatory guidelines dictate specific storage and disposal requirements for Nevramin (B-vitamin complex).


Storage Requirements

Nevramin tablets must be kept out of the sight and reach of children to prevent accidental ingestion. The product should be stored in a dry place at controlled room temperature, typically below 30 C, and must be protected from light and high heat. Always store the medicine in its original container with the lid tightly closed and do not freeze.

Disposal Instructions

Unused or expired Nevramin should be disposed of in accordance with local regulations. The preferred method is using an official drug take-back program at a pharmacy or collection site. Do not dispose of the tablets by flushing them down a toilet or pouring them down a sink, which helps prevent pharmaceutical contamination of wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Nevramin found in:

A-Z Index: